Mercer Global Advisors
ALNY icon

Mercer Global Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Mercer Global Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.46M Sell
8,156
-423
-5% -$128K ﹤0.01% 1218
2026
Q1 		$2.84M Sell
8,579
-3,207
-27% -$1.09M ﹤0.01% 1021
2025
Q4 		$4.69M Buy
11,786
+302
+3% +$134K 0.01% 742
2025
Q3 		$5.24M Buy
11,484
+8,921
+348% +$3.63M 0.01% 653
2025
Q2 		$836K Sell
2,563
-647
-20% -$179K ﹤0.01% 1307
2025
Q1 		$867K Buy
3,210
+610
+23% +$157K ﹤0.01% 1205
2024
Q4 		$612K Buy
+2,600
New +$684K ﹤0.01% 1338

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mercer Global Advisors's ALNY Position: Q2 2026 in Review

Mercer Global Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 4.9% in Q2 2026, selling an estimated $128K and leaving 8,156 shares worth $2.46M. The position accounts for ﹤0.01% of the portfolio, ranked #1218.

Mercer Global Advisors first reported a position in ALNY in Q4 2024 and has held it in 7 quarters since. The position peaked at $5.24M in Q3 2025. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Mercer Global Advisors held 8,156 shares of Alnylam Pharmaceuticals worth $2.46M as of Q2 2026.
  • Mercer Global Advisors sold 423 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $128K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #1218 holding.
  • Mercer Global Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Mercer Global Advisors's Alnylam Pharmaceuticals position peaked at $5.24M in Q3 2025.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.